Zenotech Laboratories Ltd.

51.00 -0.31 ▼-0.6%

29 May 2023, 10:07:00 AM
Volume: 2,161

Company Profile

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.zenotechlab.com
Market Cap 313.15 Cr.
Enterprise Value(EV) 313.15 Cr. 2023-03
Financial Indicators
Earnings per share (EPS) 1.90 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) 27.03 Trailing Twelve Months Ending 2023-03
Industry PE 31.87 Trailing Twelve Months Ending 2023-03
Book Value / Share 13.48 Trailing Twelve Months Ending 2023-03
Price to Book Value 3.81 Calculated using Price: 51.31
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 6.10 Cr. 61,030,568 Shares
FaceValue 10
About Zenotech Laboratories Ltd.
Zenotech Laboratories Ltd, formerly known as Sunline Technologies Limited, was originally incorporated as Maa Shakti Tube Mill private Limited on June 15,1989. Zenotech develops and manufactures generic biopharmaceuticals and markets them to people with unmet medical needs around the world.

Zenotech Laboratories Ltd. Delivery

Delivered Qty
Traded Qty

Zenotech Laboratories Ltd. Performance

1 Day
-0.60%
1 Week
-1.92%
1 Month
-7.79%
3 Month
+1.69%
6 Month
-20.93%
1 Year
-10.37%
2 Year
+22.89%
5 Year
+31.61%
10 Year
+87.57%

Zenotech Laboratories Ltd. Fundamental Ratios

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) -155.73 -7.73 24.35 -2.48 37.26
Return on Capital Employed (%) -39.28 -61.52 -65.68 -61.88 -5.95 18.32 0.48 15.26
Return on Assets (%) -33.32 -45.43 -32.82 -38.33 -17.89 -3.76 12.67 -1.42 26.45

Zenotech Laboratories Ltd. Balance Sheet

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03* Rs. Cr.
Shh. Funds 3 -27 -46 -66 42 39 50 48 71 82
Non Curr. Liab. 1 0 0 0 0 0 0 22 -4 -7
Curr. Liab. 66 91 99 116 39 45 35 15 16 17
Minority Int.
Equity & Liab. 70 64 53 51 82 85 86 86 82 92
Non Curr. Assets 59 55 50 49 50 65 80 79 74 75
Curr. Assets 11 8 3 2 31 19 6 7 7 16
Misc. Exp. not W/O
Total Assets 70 64 53 51 82 85 86 86 82 92

Zenotech Laboratories Ltd. Profit and Loss

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. TTM
Net Sales 3 4 2 2 11 13 26 22 37 42
Other Income 3 0 0 0 2 5 1 0 1 1
Total Income 5 4 2 2 14 18 27 23 37 44
Total Expenditure -20 -24 -10 -13 -19 -17 -17 -16 -19 -22
PBIDT -15 -20 -8 -10 -6 1 10 7 18 22
Interest -5 -7 -8 -8 -2 0 -1 -2 -1 0
Depreciation -4 -4 -4 -4 -4 -4 -5 -6 -7 -7
Taxation 12 -3
Exceptional Items 2 6
PAT -23 -30 -19 -20 -12 -3 11 -1 22 12
Adjusted EPS -6 -8 -5 -5 -2 -1 2 0 4 2

Zenotech Laboratories Ltd. Cash Flow

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. -10 -24 -8 -5 2 -16 -14 11 6 18
Cash Fr. Inv. 0 -1 0 6 -1 -3 -16 -21 -5 -2
Cash Fr. Finan. 10 30 7 -1 -1 47 15 -3 0 -16
Net Change 0 5 -1 0 0 28 -15 -12 1 0
Cash & Cash Eqvt 2 6 6 0 0 28 13 1 2 2

Zenotech Laboratories Ltd. Shareholding Pattern

9 Qtrs 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%)
Promoter 68.84 68.84 68.84 68.84 68.84 68.84 68.84 68.84 68.84
Public 31.16 31.16 31.16 31.16 31.16 31.16 31.16 31.16 31.16
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Zenotech Laboratories Ltd. Announcements

Mon, 22 May 2023
Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the Listing Regulations we enclose herewith the Annual Secretarial Compliance Report for the Financial Year ended March 31 2023 issued by Mr. Mahadev Tirunagari Practicing Company Secretary Hyderabad.
Wed, 03 May 2023
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyZENOTECH LABORATORIES LTD.
2CIN NO.L27100TG1989PLC010122
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 0.00
4Highest Credit Rating during the previous FY NA
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: Abdul Gafoor Mohammad
Designation: Company Secretary and Compliance Officer
EmailId: abdul.gafoor@zenotech.co.in
Name of the Chief Financial Officer: Poly K V
Designation: Chief Financial Officer
EmailId: polykv@zenotec.co.in

Date: 03/05/2023

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Fri, 28 Apr 2023
Submission Of Audited Standalone Financial Results Of Zenotech Laboratories Limited ('The Company') For The Quarter And Financial Year Ended March 31 2023
Pursuant to the Regulation 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform that the Board of Directors of the Company at its meeting held today i.e. April 28 2023 have considered and approved the Audited Standalone Financial Results of the Company for the quarter and financial year ended on March 31 2023 along with the Report of Auditors thereon andA Declaration (Unmodified opinion) under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 is also enclosed. The meeting of the Board of Directors commenced at 5:30 PM and concluded at 7:50 PM.The aforesaid information is also being uploaded on the Companys website at www.zenotechlab.com.

Zenotech Laboratories Ltd. Technical Scans

Fri, 26 May 2023
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Closing Below Previous Low Closing Below Previous Low
Close Within 52 Week Low Zone Close Within 52 Week Low Zone

Zenotech Laboratories Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 232,891.45 955.60 -1.5%
Divi's Laboratories Ltd. 93,212.66 3,489.35 -0.7%
Cipla Ltd. 76,767.04 946.45 -0.5%
Dr. Reddy's Laboratories Ltd. 75,437.96 4,563.40 +0.7%
Apollo Hospitals Enterprise Ltd. 66,286.16 4,594.45 -0.3%
Torrent Pharmaceuticals Ltd. 57,611.88 1,702.70 +0.1%
Mankind Pharma Ltd. 53,007.87 1,369.00 +3.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 27.48 955.60 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 51.00 3,489.35 -0.7%
Cipla Ltd. Consolidated 2023-03 27.40 946.45 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 16.74 4,563.40 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 86.68 4,594.45 -0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 69.29 1,702.70 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 39.70 1,369.00 +3.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 4.16 955.60 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 7.28 3,489.35 -0.7%
Cipla Ltd. Consolidated 2023-03 3.28 946.45 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 3.24 4,563.40 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-12 10.75 4,594.45 -0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 9.03 1,702.70 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 5.10 1,369.00 +3.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 955.60 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,489.35 -0.7%
Cipla Ltd. Consolidated 2022-03 0.04 946.45 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,563.40 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,594.45 -0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,702.70 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 0.14 1,369.00 +3.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 955.60 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,489.35 -0.7%
Cipla Ltd. Consolidated 2022-03 13.10 946.45 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,563.40 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,594.45 -0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,702.70 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 26.72 1,369.00 +3.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 955.60 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,489.35 -0.7%
Cipla Ltd. Consolidated 2022-03 13.10 946.45 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.93 4,563.40 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,594.45 -0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,702.70 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 26.72 1,369.00 +3.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 955.60 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,489.35 -0.7%
Cipla Ltd. Consolidated 2022-03 21,763.34 946.45 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,563.40 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,594.45 -0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,702.70 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 7,781.56 1,369.00 +3.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 955.60 -1.5%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,489.35 -0.7%
Cipla Ltd. Consolidated 2022-03 2,559.47 946.45 -0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,182.50 4,563.40 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,594.45 -0.3%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,702.70 +0.1%
Mankind Pharma Ltd. Standalone 2022-03 1,452.96 1,369.00 +3.4%

Zenotech Laboratories Ltd. FAQ's

What is Zenotech Laboratorie share price?

Can I buy Zenotech Laboratorie shares now?

What is the Market Cap of Zenotech Laboratorie?

What are the key metrics to analyse Zenotech Laboratorie?

What is the 52 Week High and Low of Zenotech Laboratorie?

What is the trend of Zenotech Laboratorie share price?